0001209191-20-025306.txt : 20200421
0001209191-20-025306.hdr.sgml : 20200421
20200421184745
ACCESSION NUMBER: 0001209191-20-025306
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200417
FILED AS OF DATE: 20200421
DATE AS OF CHANGE: 20200421
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CHALMERS DEREK T
CENTRAL INDEX KEY: 0001166287
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36279
FILM NUMBER: 20806248
MAIL ADDRESS:
STREET 1: C/O CARA THERAPEUTICS, INC.
STREET 2: 1 PARROTT DRIVE
CITY: SHELTON
STATE: CT
ZIP: 06484
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cara Therapeutics, Inc.
CENTRAL INDEX KEY: 0001346830
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4 STAMFORD PLAZA
STREET 2: 107 ELM STREET 9TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06902
BUSINESS PHONE: 203-406-3700
MAIL ADDRESS:
STREET 1: 4 STAMFORD PLAZA
STREET 2: 107 ELM STREET 9TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06902
FORMER COMPANY:
FORMER CONFORMED NAME: Cara Therapeutics Inc
DATE OF NAME CHANGE: 20051213
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-04-17
0
0001346830
Cara Therapeutics, Inc.
CARA
0001166287
CHALMERS DEREK T
C/O CARA THERAPEUTICS, INC.
4 STAMFORD PLAZA, 107 ELM ST, 9TH FLOOR
STAMFORD
CT
06902
1
1
0
0
President & CEO
Common Stock
2020-04-17
4
A
0
20000
0.00
A
987769
D
Common Stock
2020-04-21
4
S
0
6348
15.56
D
981421
D
Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on April 17, 2020. The vested shares represent the total number of remaining shares subject to the award. Each RSU represents the contingent right to receive one share of common stock of the Issuer.
This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the RSUs reported herein as described in greater detail in footnote (1), and does not represent a discretionary trade by the Reporting Person.
Represents the number of shares required to be sold by the Reporting Person to cover tax withholding as described in footnote (2).
/s/Darren DeStefano, Attorney-in-Fact
2020-04-21